Shanghai Heben-Eastsun Medicaments Co., Ltd. was established in March 2002, which was located in Jinshan Industrial Park of Shanghai. The company covers an area of 2.7 hectares, with 12 large standardized plants. Shanghai Heben is mainly engaged in the R&D, production and sales of agrochemicals, with capacity of 5000MT/year for WDG and WP and 3000MT/year for SC. In 2010, Shanghai Heben was the first company in China to get the ICAMA of Azoxystrobin, as well as Pyraclostrobin. In September 2013,Shanghai Heben was rated as Shanghai high-tech enterprise. In 2014, it was awarded the patent of Tebuconazole, Carbendazim WDG and its processing method. In addition, Shanghai Heben has the high-tech achievement project of Dimethomorph 50% WDG, Tebuconazole 80% WDG and Carbendazim 90% WDG.In October 2020, new technical factory in Jiangxi with 10 hectares began the operation and production.It is going to expand the production capacity of Azoxystrobin from 1500MT/year to 3000MT/ year before October 2023. In addition, Other active technical projects such as Chlorfenapyr, Lufenuron, Fludioxonil, Pyraclostrobin are being prepared.Shanghai Heben adheres to the technology-based and market-oriented development concept, keeps up with the latest trends in agrochemicals' development in the domestic and overseas, increases investment in technology, and continues to launch products that meet market development requirements. In addition, Shanghai Heben also builds the core competitiveness of the enterprise by continuously improving technology and marketing promotion services, and wholeheartedly provides high-quality solutions for partners engaged in plant protection in the domestic and overseas. Shanghai Heben has always been adhering to the development concept of "pursuing excellence, win-win cooperation, and winning through innovation", responding to the call of the country's sustainable development, and striving to become an excellent agrochemicals enterprise in China.